What are Alnylam Pharmaceuticals's profit margins?

Alnylam Pharmaceuticals (ALNY) runs a 81.0% gross margin and a 17.5% operating margin, with a 11.7% net margin.

Where do Alnylam Pharmaceuticals's ratios come from?

Every ratio is computed from Alnylam Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.

Alnylam Pharmaceuticals ALNY Ratios & Valuation

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Profitability
Gross margin	330.7%-5.3pp	336%-4.6pp	340.6%-2.8pp	343.4%-4.5pp	347.8%+0.3pp
Operating margin	32%+22.5pp	9.5%+21.4pp	-11.9%+17.2pp	-29.1%-11.7pp	-17.4%+3.9pp
Net margin	10.4%+21.5pp	-11.1%+19.9pp	-31%+18.4pp	-49.4%-8.3pp	-41.2%+6.8pp
Efficiency
Asset turnover	3×+0.3×	2.7×+0.2×	2.4×+0.2×	2.2×-0.1×	2.3×0.0×
Liquidity
Current ratio	11.2×+0.1×	11.1×0.0×	11.2×-0.2×	11.4×-0.2×	11.6×-0.1×
Leverage
Debt-to-equity	2.8×-0.4×	3.2×-3.7×	6.9×-7.5×	14.4×—	——
Per Share
Book value per share	$17.26+35.2%	$12.77+71.8%	$7.43+24.3%	$5.98+48.1%	$4.04+510%
Valuation
Market capitalization	$198.56B+4.7%	$189.63B+13.2%	$167.45B+17.1%	$142.98B+8.9%	$131.34B+14.0%
Price / sales	60.2×-4.6×	64.9×+0.6×	64.2×+1.8×	62.5×+4.1×	58.3×+5.5×
Price / book	532×-41.2×	573.2×-386×	959.1×-836×	1,794.8×—	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Alnylam Pharmaceuticals.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Alnylam Pharmaceuticals's profit margins?: Alnylam Pharmaceuticals (ALNY) runs a 81.0% gross margin and a 17.5% operating margin, with a 11.7% net margin.
Where do Alnylam Pharmaceuticals's ratios come from?: Every ratio is computed from Alnylam Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.